Weathering one of biotech’s worst bear markets

As the biotech industry endures one of the worst bear markets in the sector’s history, investors are drawing up their priorities to weather the downturn. Cash, liquidity and managerial experience top the list.

It has been over a decade since the biotech sector was faced with an extended bear market, and about 20 years since the NASDAQ bubble burst in 2002-03. Both events have come to mind for experienced healthcare investors this year, as they’ve watched biotech indexes nearly double their 2021 losses in the space of a month...